Sugi Predict

Sugi Predict / Compounds / SCHEMBL6451941

SCHEMBL6451941

SCHEMBL6451941

N[C@H](C(=O)O)C(c1ccccc1)[N+](=O)[O-]

nearest known ligand 0.49

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ CYP2D6 P10635 1/20 0.42
▸ SRC P12931 1/20 0.42
▸ DPP4 P27487 2/20 0.41
▸ LMNA P02545 2/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ SLC1A2 P43004 3/20 0.41
▸ SLC1A3 P43003 2/20 0.41
▸ SLC1A1 P43005 2/20 0.41
▸ GRM2 Q14416 1/20 0.39
▸ GRM3 Q14832 1/20 0.39
▸ GSR P00390 1/20 0.39
▸ GABBR2 O75899 1/20 0.38
▸ GABBR1 Q9UBS5 1/20 0.38
▸ CPA1 P15085 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6451939 1.00 CYP2D6 (0.42) CYP2D6SRCDPP4LMNAMAPK1
SCHEMBL14935824 1.00 CYP2D6 (0.42) CYP2D6SRCDPP4LMNAMAPK1
SCHEMBL7678184 0.86 TDP1 (0.40) CYP2D6SRCLMNASLC1A2SLC1A3
SCHEMBL457188 0.86 TDP1 (0.40) CYP2D6SRCLMNASLC1A2SLC1A3
SCHEMBL9617913 0.81 SRC (0.45) CYP2D6SRCLMNAMAPK1GSR
SCHEMBL6281430 0.80 LMNA (0.46) CYP2D6SRCDPP4LMNAMAPK1
SCHEMBL6809341 0.79 CYP2D6 (0.59) CYP2D6SRCLMNAMAPK1GSR
SCHEMBL1667445 0.77 GABBR2 (0.50) CYP2D6GSRGABBR2GABBR1
SCHEMBL18193017 0.76 GSR (0.43) CYP2D6SRCDPP4LMNAMAPK1
SCHEMBL28497474 0.75 GSR (0.42) CYP2D6LMNAMAPK1GSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 223 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024241086-A1 PEGYLATED BOVINE INTERFERON LAMBDA AND METHODS OF USE THEREOF AMBRX, INC. (US) 2024-11-28 — — WO claimed
WO-2024215515-A1 DRUG LINKERS AND ANTIBODY CONJUGATES THEREOF AMBRX, INC. (US) 2024-10-17 — — WO claimed
CN-114457049-B Pyrrolysiyl-tRNA synthetase mutant and application thereof 浙江大学杭州国际科创中心 2024-09-24 — — CN claimed
WO-2024178310-A1 TROP2-DIRECTED ANTIBODY-DRUG CONJUGATES AND USES THEREOF AMBRX, INC. (US) 2024-08-29 — — WO claimed
CN-114457049-A Pyrrolysinyl-tRNA synthetase mutant and application thereof 浙江大学杭州国际科创中心 2022-05-10 — — CN claimed
US-20160022636-A1 PHYSIOLOGICAL LIGANDS FOR GPR139 JANSSEN PHARMACEUTICA NV (BE) 2016-01-28 — — US claimed
EP-2968240-A2 PHYSIOLOGICAL LIGANDS FOR GPR139 Janssen Pharmaceutica, N.V. (BE) 2016-01-20 — — EP claimed
US-20140336216-A1 PHYSIOLOGICAL LIGANDS FOR GPR139 JANSSEN PHARMACEUTICA NV (BE) 2014-11-13 — — US claimed
WO-2014152917-A2 PHYSIOLOGICAL LIGANDS FOR GPR139 JANSSEN PHARMACEUTICA NV (BE) 2014-09-25 — — WO claimed
US-20260083834-A1 CsgA-DERIVED NANOSTRUCTURES AND USES THEREOF FOR ANTIGEN DELIVERY TRANSFERT PLUS LP (CA) 2026-03-26 — — US disclosed
US-20250367300-A1 Nanomaterial and Methods of Use Thereof UNIVERSITY OF CONNECTICUT (US) 2025-12-04 — — US disclosed
EP-4651906-A1 ANTI-CD70 ANTIBODY-DRUG CONJUGATES Ambrx, Inc. (US) 2025-11-26 — — EP disclosed
WO-2025235287-A1 ENGINEERED TRNAS AND COGNATE SYNTHETASES FOR QUADRUPLET DECODING AND INCORPORATION OF NON-CANONICAL AMINO ACIDS THE SCRIPPS RESEARCH INSTITUTE (US) 2025-11-13 — — WO disclosed
US-20250302762-A1 NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF UNIVERSITY OF CONNECTICUT (US) 2025-10-02 — — US disclosed
US-8927500-B2 Peptidomimetic macrocycles AILERON THERAPEUTICS, INC. (US) 2015-01-06 — — US disclosed
US-20140336216-A1 PHYSIOLOGICAL LIGANDS FOR GPR139 JANSSEN PHARMACEUTICA NV (BE) 2014-11-13 — — US disclosed
US-20130274205-A1 PEPTIDOMIMETIC MACROCYCLES AILERON THERAPEUTICS, INC. 2013-10-17 — — US disclosed
US-20130210745-A1 TRIAZOLE-CROSSLINKED AND THIOETHER-CROSSLINKED PEPTIDOMIMETIC MACROCYCLES AILERON THERAPEUTICS, INC. (US) 2013-08-15 — — US disclosed
US-20130123169-A1 PEPTIDOMIMETIC MACROCYCLES AILERON THERAPEUTICS, INC. (US) 2013-05-16 — — US disclosed
US-20050256095-A1 Asthma and colitis treatment methods BIOVIE INC. 2005-11-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250367300-A1 Nanomaterial and Methods of Use Thereof EPCAM, CD47, JAK2 CYP2D6 893/4885SRC 621/4885DPP4 1271/4885
US-20250302762-A1 NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF JAK2, JAK1, CHMP4B CYP2D6 1980/4885SRC 725/4885DPP4 3265/4885
US-20260083834-A1 CsgA-DERIVED NANOSTRUCTURES AND USES THEREOF FOR ANTIGEN DELIVERY VSIG8, MICA, CD74 CYP2D6 4548/4885SRC 3967/4885DPP4 3067/4885
US-20130123169-A1 PEPTIDOMIMETIC MACROCYCLES GHRHR, GHSR, GHITM CYP2D6 4688/4885SRC 1532/4885DPP4 265/4885
US-20050256095-A1 Asthma and colitis treatment methods HSD3B1, HSD17B1, HSD11B1 CYP2D6 288/4885SRC 3401/4885DPP4 3050/4885
US-20130210745-A1 TRIAZOLE-CROSSLINKED AND THIOETHER-CROSSLINKED PEPTIDOMIMETIC MACROCYCLES IL33, TPR, CDC37 CYP2D6 4191/4885SRC 696/4885DPP4 677/4885
US-20130274205-A1 PEPTIDOMIMETIC MACROCYCLES PROKR1, GLP1R, PROKR2 CYP2D6 4561/4885SRC 733/4885DPP4 128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.